Bosutinib

Drug Profile

Bosutinib

Alternative Names: Bosulif; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Avillion; Massachusetts General Hospital; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class Aniline compounds; Antineoplastics; Nitriles; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Acute lymphoblastic leukaemia
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 28 Apr 2017 Pfizer plans a phase II trial for Chronic myeloid leukaemia (Newly diagnosed, Monotherapy) (NCT03128411)
  • 03 Dec 2016 Efficacy and adverse event data from a pooled analysis in Chronic myeloid leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top